AbbVie Inc. · Q4 2024
ReportedJan 31, 2025
Period endedDec 31, 2024
Rule of 40+50
The quarter in short
Revenue $15.10B, up 5.6% year over year and 4.4% on the quarter. EPS −$0.03. Free cash flow $6.76B, up 48.6% year over year and 30.0% on the quarter. Rule of 40 score +50.
Reported this quarter
Revenue
$15.10B
QoQ +4.4%
YoY +5.6%
EPS
−$0.03
QoQ —
YoY —
Free Cash Flow
$6.76B
QoQ +30.0%
YoY +48.6%
Gross Margin
70.9%
QoQ 0.0 pp
YoY +0.1 pp
FCF Margin
44.7%
QoQ +8.8 pp
YoY +12.9 pp
P/E Ratio
71.0
QoQ +8.8%
YoY +35.2%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1551152.
HTML
8-K results announcement
Filed Jan 31, 2025
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
493 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-K annual report
Period ended Dec 31, 2024, filed Feb 14, 2025
ZIP
XBRL data bundle
Structured financial statements from the 10-K
JSON
Company facts (XBRL)
Every figure ABBV has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q4 2024, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings